SEP 22, 2016 5:10 AM PDT

Autism, Zoloft and Fragile X: New Information

 
With autism statistics at 1 in 68 children, the search for information on the causes and possible treatments is a priority for many neuroscientists. While there is no known cause of autism, it occurs in approximately 60% of children who have Fragile X syndrome so researchers are looking at ways the two disorders are connected. Fragile X is a genetic disorder that causes certain facial features like a large forehead and ears as well as intellectual disabilities, social anxiety and self-stimulating behavior like hand flapping. It occurs as a result of the expansion of the CGG trinucleotide repeat affecting the Fragile X mental retardation 1 (FMR1) gene on the X chromosome, resulting in a failure to express the fragile X mental retardation protein (FMRP), which is required for normal neural development.
 New information on Fragile X and autism
There are no treatments available for Fragile X itself, nor are there medications for most autism spectrum disorders however some children who have ADHD or anxiety along with these conditions do take medications for focus and/or stress relief. New research into how it relates to autism might offer another avenue for treatment however.
 
A study by researchers with the UC Davis MIND Institute has found that treatment with the anti-depressant drug sertraline (brand name Zoloft) may provide small but important improvements in intellectual ability and social participation in children with fragile X syndrome, but only at very young ages. The study is published online in the Journal of Developmental & Behavioral Pediatrics and is the first clinical trial to look at low doses of Zoloft for the learning and emotional issues children with the genetic disorder suffer from.  The researchers noted that language acquisition also improved in the children who took Zoloft.
 
In a press release from UC Davis Randi Hagerman, senior author and medical director of the UC Davis MIND Institute stated, “These are important outcomes that warrant further studies of sertraline in fragile X syndrome and in autism spectrum disorder. All of the families that completed the study wanted to continue their children on sertraline.”
 
Since Zoloft is a selective serotonin reuptake inhibitor (SSRI) and serotonin levels are low during early development, when synapse formation is most rapid there is a window in the first five years of a child’s life where boosting serotonin levels could improve development. This very crucial period of time in a child’s life could be the best time for treatments that involve SSRIs. Previous research in mouse models also showed that SSRIs stimulate a substance in the brain called brain-derived neurotrophic factor (BDNF) which is necessary for proper synaptic growth. Hagerman believes there could be a link between SSRIs and this development in children with Fragile X.
 
“Given the lack of maturation of synapses in fragile X syndrome, along with BDNF’s role in synaptic maturation, plasticity and neurogenesis, SSRIs are of particular interest for the treatment of fragile X syndrome,” Hagerman said.
 
The research involved 52 children between the ages of 2 and 5 who were monitored for cognitive development and social skills for a period of 3.5 years. Half of the children were given Zoloft and half a placebo. The children who received the medication showed better progress in areas of cognition and social functioning as well as language development. In the video below Dr. Hagerman explains more about the study and what it might mean for children affected by Fragile X.

Sources: UC DavisJournal of Developmental Behavioral Pediatrics, National Fragile X Foundation
 
About the Author
  • I'm a writer living in the Boston area. My interests include cancer research, cardiology and neuroscience. I want to be part of using the Internet and social media to educate professionals and patients in a collaborative environment.
You May Also Like
APR 25, 2020
Neuroscience
APR 25, 2020
Autoimmune Protein May Cause OCD
Researchers from Queen Mary University in London have discovered a specific autoimmune protein that may cause OCD-relate ...
MAY 04, 2020
Neuroscience
MAY 04, 2020
Certain Gut Bacteria Improves Memory in Mice
Researchers from the US Department of Energy national laboratories have found that certain gut bacteria are able to impr ...
MAY 04, 2020
Cannabis Sciences
MAY 04, 2020
Can Cannabis Improve Chronic Insomnia?
Around 30% of Americans have insomnia. A serious problem, researchers have found that cannabis products may be able to h ...
MAY 11, 2020
Cell & Molecular Biology
MAY 11, 2020
3D Cell Culture Model Suggests Herpes Can Cause Alzheimer's
Alzheimer's is a common form of dementia that affects as many as 5.5 million Americans and the incidence is increasing a ...
JUN 01, 2020
Neuroscience
JUN 01, 2020
New Path to Gene Therapy for ALS
Video: Todd Cohen, PhD (UNC) discusses GA protein accumulation.  At the time of this video promising research was a ...
JUN 29, 2020
Neuroscience
JUN 29, 2020
Stroke Most Common Brain Side Effect from COVID-19
Researchers from the UK have identified having a stroke as the most common neurological side-effect of COVID-19. They al ...
Loading Comments...